[go: up one dir, main page]

UY35275A - Derivados de aminopirazina - Google Patents

Derivados de aminopirazina

Info

Publication number
UY35275A
UY35275A UY0001035275A UY35275A UY35275A UY 35275 A UY35275 A UY 35275A UY 0001035275 A UY0001035275 A UY 0001035275A UY 35275 A UY35275 A UY 35275A UY 35275 A UY35275 A UY 35275A
Authority
UY
Uruguay
Prior art keywords
aminopirazine
derivatives
compounds
processes
formula
Prior art date
Application number
UY0001035275A
Other languages
English (en)
Inventor
Craig Steven Harris
Gary Peter Tomkinson
Ouvry Gilles
Bernard Christophe Barlaam
Delouvrie Benedicte
Marie Christine
Paul Lambert-Van Der Brempt
Berry David
Gary Patrick Reid
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY35275A publication Critical patent/UY35275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con compuestos de Fórmula (I) N N N N N N O N N NH2 R 1 O R 2 (I) o sales farmacéuticamente aceptables de los mismos, en donde R1 y R2 tienen cualquiera de los significados definidos anteriormente en la prese nte en la descripción; procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en el tratamiento de trastornos prolife rativos celulares.
UY0001035275A 2013-01-23 2014-01-23 Derivados de aminopirazina UY35275A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13305078 2013-01-23

Publications (1)

Publication Number Publication Date
UY35275A true UY35275A (es) 2014-07-31

Family

ID=47623992

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035275A UY35275A (es) 2013-01-23 2014-01-23 Derivados de aminopirazina

Country Status (26)

Country Link
US (2) US9156831B2 (es)
EP (1) EP2948447B1 (es)
JP (1) JP6307096B2 (es)
KR (1) KR102202516B1 (es)
CN (1) CN104936953B (es)
AP (1) AP2015008604A0 (es)
AR (1) AR094553A1 (es)
AU (1) AU2014208964B2 (es)
BR (1) BR112015017331B1 (es)
CA (1) CA2897279C (es)
CL (1) CL2015002027A1 (es)
CR (1) CR20150367A (es)
DO (1) DOP2015000170A (es)
ES (1) ES2608395T3 (es)
IL (1) IL239890A0 (es)
MA (1) MA38287B1 (es)
MX (1) MX361136B (es)
NI (1) NI201500096A (es)
PE (1) PE20151979A1 (es)
PH (1) PH12015501584A1 (es)
RU (1) RU2644769C2 (es)
SG (1) SG11201505631PA (es)
TN (1) TN2015000313A1 (es)
TW (1) TWI606047B (es)
UY (1) UY35275A (es)
WO (1) WO2014114928A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
TW201726140A (zh) * 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN107137405A (zh) * 2017-04-14 2017-09-08 黄德莲 一种治疗肾炎的药物组合物
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑-羧酸酯类衍生物在医药领域的应用
MX2021004775A (es) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
JP2022509019A (ja) 2018-11-05 2022-01-20 シンジェンタ パーティシペーションズ アーゲー 殺有害生物的に活性なアゾール－アミド化合物
US20220167618A1 (en) 2019-03-08 2022-06-02 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
BR112021018495A2 (pt) 2019-03-20 2021-11-30 Syngenta Crop Protection Ag Compostos de azolamida ativos em termos pesticidas
EP3941914A1 (en) 2019-03-22 2022-01-26 Syngenta Crop Protection AG N-[1-(5-bromo-2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-2-cyclopropyl-6-(trifluoromethyl)pyridine-4-carboxamide derivatives and related compounds as insecticides
PH12022552755A1 (en) 2020-04-24 2024-03-25 Astrazeneca Ab Pharmaceutical formulations
CN114788829B (zh) * 2021-01-25 2023-06-20 广州嘉越医药科技有限公司 一种吡啶并[1,2-a]嘧啶酮类似物的应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (es) 1970-09-25 1972-03-28
US4256887A (en) 1978-04-06 1981-03-17 Merck & Co., Inc. 1,2,4-Triazoles and a method for their preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JP3028168B2 (ja) 1993-03-29 2000-04-04 住化ファインケム株式会社 ベンゼンスルホンアミド誘導体の製造方法
US5656416A (en) 1994-12-22 1997-08-12 Eastman Kodak Company Photographic processing composition and method using organic catalyst for peroxide bleaching agent
NZ301265A (en) 1995-02-02 1998-12-23 Smithkline Beecham Plc Indole derivatives as 5ht receptor antagonists, preparation and pharmaceutical compositions thereof
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
CA2260900A1 (en) 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited Substituted triazolo pyridazine derivatives as inverse agonists of the gabaa.alpha.5 receptor subtype
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
EP1303507A1 (en) 2000-07-19 2003-04-23 F. Hoffmann-La Roche Ag Pyrimidine derivatives
WO2003045924A1 (en) 2001-11-21 2003-06-05 Pharmacia & Upjohn Company Substituted aryl 1,4-pyrazine derivatives
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
EP1467986A1 (en) 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
WO2003093297A2 (en) 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
GB0306097D0 (en) 2003-03-15 2003-04-23 Elam T Ltd Electroluminescent complexes
JP2006520794A (ja) 2003-03-21 2006-09-14 スミスクライン ビーチャム コーポレーション 化合物
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
ES2389203T3 (es) 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
EP1742935B1 (en) 2004-04-13 2010-02-24 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
JP2006028056A (ja) 2004-07-14 2006-02-02 Agro Kanesho Co Ltd ピリミジン誘導体及びこれを含む有害生物防除剤
EP1786790B1 (en) 2004-07-26 2009-06-03 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
CA2589084A1 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
AU2006258124B8 (en) 2005-06-10 2010-01-07 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
RU2008141761A (ru) 2006-03-22 2010-04-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
JP2009541268A (ja) 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
US20090306039A1 (en) 2006-07-21 2009-12-10 Shifeng Pan Compounds and compositions as itpkb inhibitors
KR101438245B1 (ko) 2006-08-23 2014-09-04 쿠도스 파마슈티칼스 리미티드 Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체
EP2151437A4 (en) 2007-03-07 2012-05-02 Nissan Chemical Ind Ltd ISOXAZOLINE SUBSTITUTED BENZAMIDE COMPOUND AND PEST CONTROL AGENT
EA020996B1 (ru) 2007-08-14 2015-03-31 Байер Интеллекчуал Проперти Гмбх Конденсированные бициклические пиримидины
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
PT2201012E (pt) 2007-10-11 2014-09-04 Astrazeneca Ab Derivados de pirrolo[2,3-d]piridina como inibidores da proteína quinase b
KR20100089090A (ko) 2007-10-25 2010-08-11 아스트라제네카 아베 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
JPWO2009072621A1 (ja) 2007-12-07 2011-04-28 日産化学工業株式会社 置換ジヒドロアゾール化合物及び有害生物防除剤
CN101939319A (zh) 2007-12-20 2011-01-05 诺瓦提斯公司 联噻唑衍生物、它们的制备方法以及它们作为药物的用途
CA2709918A1 (en) 2007-12-21 2009-06-25 The Scripps Research Institute Benzopyrans and analogs as rho kinase inhibitors
EP2310391A1 (en) 2008-06-27 2011-04-20 S*BIO Pte Ltd Pyrazine substituted purines
EP2342190A1 (en) 2008-09-02 2011-07-13 Novartis AG Bicyclic kinase inhibitors
JP2010083883A (ja) 2008-09-08 2010-04-15 Nissan Chem Ind Ltd イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP2010063863A (ja) 2008-09-11 2010-03-25 Mugen:Kk ヘッドのフェース部背面に音響振動の異なるパイプまたは平板を複数設けた打点位置表示型ゴルフ練習用クラブとその製法
CN101676271B (zh) 2008-09-17 2011-12-14 山东轩竹医药科技有限公司 含有不饱和杂环胺的四环素衍生物
MX2011004953A (es) 2008-11-10 2011-12-14 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
EA022271B1 (ru) * 2008-11-14 2015-12-30 Байер Интеллектуэль Проперти Гмбх Гетероциклические замещенные соединения арила в качестве ингибиторов hif
MX2011006503A (es) * 2008-12-19 2011-09-06 Vertex Pharma Derivados de pirazina utiles como inhibidores de la cinasa de atr.
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
KR20110114663A (ko) 2009-02-13 2011-10-19 바이엘 파마 악티엔게젤샤프트 융합된 피리미딘
ES2435804T3 (es) * 2009-02-13 2013-12-23 Bayer Intellectual Property Gmbh Pirimidinas condensadas como inhibidores de Akt
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
GB0909441D0 (en) 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EP2470021B1 (en) 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
CN102666545B (zh) 2009-10-20 2016-04-06 塞尔卓姆有限公司 作为jak抑制剂的杂环吡唑并嘧啶类似物
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
SG182803A1 (en) 2010-02-05 2012-09-27 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
JP2011178673A (ja) 2010-02-26 2011-09-15 Nissan Chem Ind Ltd 非農園芸害虫の防除方法
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
WO2012037226A1 (en) * 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
SG188302A1 (en) * 2010-09-16 2013-04-30 Hutchison Medipharma Ltd Fused heteroaryls and their uses
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CN102718745A (zh) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CA2837312A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof
WO2013049591A2 (en) 2011-09-29 2013-04-04 Verseon Corporation Dual inhibitor compounds and methods of use thereof
WO2013152298A1 (en) 2012-04-05 2013-10-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof

Also Published As

Publication number Publication date
ES2608395T3 (es) 2017-04-10
NI201500096A (es) 2016-02-16
CR20150367A (es) 2015-10-20
RU2644769C2 (ru) 2018-02-14
BR112015017331A8 (pt) 2019-11-12
AU2014208964A1 (en) 2015-08-06
BR112015017331A2 (pt) 2017-07-11
TN2015000313A1 (en) 2017-01-03
BR112015017331B1 (pt) 2022-01-11
AP2015008604A0 (en) 2015-07-31
MX361136B (es) 2018-11-28
EP2948447A1 (en) 2015-12-02
US9657008B2 (en) 2017-05-23
CN104936953B (zh) 2017-03-08
US20140206700A1 (en) 2014-07-24
IL239890A0 (en) 2015-08-31
WO2014114928A1 (en) 2014-07-31
MX2015009465A (es) 2015-09-28
CA2897279A1 (en) 2014-07-31
CL2015002027A1 (es) 2015-11-13
MA38287A1 (fr) 2018-01-31
CN104936953A (zh) 2015-09-23
CA2897279C (en) 2020-12-29
DOP2015000170A (es) 2015-08-16
TWI606047B (zh) 2017-11-21
MA38287B1 (fr) 2018-08-31
JP2016508484A (ja) 2016-03-22
AR094553A1 (es) 2015-08-12
US9156831B2 (en) 2015-10-13
PE20151979A1 (es) 2016-01-15
KR20150109385A (ko) 2015-10-01
US20160137634A1 (en) 2016-05-19
KR102202516B1 (ko) 2021-01-12
AU2014208964B2 (en) 2016-09-01
EP2948447B1 (en) 2016-09-21
HK1214592A1 (en) 2016-07-29
PH12015501584A1 (en) 2015-10-05
RU2015132370A (ru) 2017-03-02
SG11201505631PA (en) 2015-08-28
JP6307096B2 (ja) 2018-04-04
TW201522329A (zh) 2015-06-16

Similar Documents

Publication Publication Date Title
UY35275A (es) Derivados de aminopirazina
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
NI201900039A (es) Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer
NI201500167A (es) Compuestos químicos
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2019001993A1 (es) Inhibidores selectivos de jak1.
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
PH12015502632A1 (en) Cxcr7 receptor modulators
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
UY35536A (es) ?derivados de sulfonamida?.
ECSP18056196A (es) Derivados de indano
ECSP13012372A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
UY36958A (es) Compuestos para administración intracelular
TH158992A (th) อนุพันธ์เบนซิมิดาโซล-โปรลีน
CL2012001818A1 (es) Compuestos derivados de 3-oxo-piridazina sustituida, antagonista b1, composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor y/o osteoartritis.
CU20100172A7 (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211028